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Association of circulating 
calprotectin with lipid profile in 
axial spondyloarthritis
Fernanda Genre1, Javier Rueda-Gotor1, Sara Remuzgo-Martínez1, Alfonso Corrales1, 
Verónica Mijares1, Rosa Expósito2, Cristina Mata2, Virginia Portilla1, Ricardo Blanco1, 
José Luis Hernández3, Javier Llorca4, Oreste Gualillo  5, Raquel López-Mejías  1 & 
Miguel A. González-Gay1,6,7
Calprotectin (CPT) is released during inflammation, also in the context of atherosclerosis. The link 
between CPT and the atherosclerotic process was evaluated in several diseases. However, studies in 
axial spondyloarthritis (axSpA), associated with a high incidence of subclinical atherosclerosis, are 
scarce. Therefore, we assessed the association of CPT with subclinical atherosclerosis and metabolic 
risk factors in axSpA. CPT serum levels were measured by enzyme-linked immunosorbent assay in 
163 axSpA patients and 63 controls. Subclinical atherosclerosis was determined in patients by carotid 
ultrasonography (assessing the presence/absence of carotid plaques and carotid intima-media thickness 
[cIMT]). Data on inflammation, disease activity, lipid profile and treatment were collected to evaluate 
its relationship with CPT. axSpA patients evidenced lower CPT levels than controls. CPT showed no 
association with plaques or cIMT in axSpA. CPT and HDL-cholesterol negatively correlated, while a 
positive association of CPT with the atherogenic index was disclosed. Additionally, axSpA patients 
with C-reactive protein values at diagnosis higher than 3 mg/L displayed higher CPT levels. Our study 
shows no relationship between CPT and markers of subclinical atherosclerosis in axSpA. Nevertheless, 
it demonstrates an association of CPT with adverse lipid profiles and inflammatory biomarkers, which 
could further influence on the development of atherosclerosis.
Several metabolic abnormalities such as hyperglycemia, dyslipidemia, obesity and hypertension are consid-
ered risk factors for the development of cardiovascular (CV) disease. Most of them are clustered under the term 
‘Metabolic syndrome’ (MeS), a pathologic state with growing prevalence that has been associated with the devel-
opment not only of vascular and cardiac diseases, but also with other pathologies1–5.
CV disease is generally the result of an accelerated atherosclerotic process, initiated by damage to the vas-
cular endothelium. This can lead to structural damage, manifested by thickening of the vascular wall (carotid 
intima-media thickness [cIMT]) as well as atheromatous plaque formation6. These morphological findings are 
considered surrogate markers of CV disease. In this sense, both in the general population and in patients with 
chronic inflammatory arthritis, an abnormal cIMT value or the presence of plaques predict the development 
of CV events such as ischemic heart disease or stroke7–11. As previously shown by our group, the presence of 
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these two surrogate markers of CV disease can be determined by carotid ultrasound, a non-invasive imaging 
technique10–12.
Patients diagnosed with chronic inflammatory diseases, such as axial spondyloarthritis (axSpA), show higher 
morbidity and mortality rates due to CV disease, particularly atherosclerosis, when compared to the general pop-
ulation6,13,14. This is not only the result of a higher incidence of traditional CV risk factors and MeS features15–20, 
but also due to the inflammatory burden present in these patients, that acts as an additional independent CV risk 
factor21,22. In this regard, it is well known that inflammation triggers the expression of endothelial adhesion mole-
cules, promoting thus endothelial damage and the formation of atherosclerotic plaques, an indicator of advanced 
atherosclerosis22.
Among the cells implicated in the development of atherosclerotic disease, neutrophils, monocytes and mac-
rophages play a key role by secreting a large number of molecules which are further involved in the inflamma-
tory process of atherosclerosis23. In this context, calprotectin (CPT), also known as myeloid-related protein 8/14 
(MRP8/14) or S100A8/A9, is a heterodimeric complex of proteins released by these cells during inflammation24. 
In fact, it was reported that the secretion of CPT is stimulated by the interaction between phagocytes and the 
endothelium25. Accordingly, the link between CPT and the pathophysiology of atherosclerosis has been studied 
in several diseases26–29. However, previous studies on this issue that included axSpA patients are limited to only 
one performed in a small cohort of patients with different inflammatory arthropaties30.
Regarding the functional role of CPT, this protein exerts diverse intra- and extra-cellular functions, acting on 
different target tissues/organs, such as muscle, cartilage, bone, synovial tissue, vasculature and epithelium, among 
others31. Modulation of the inflammatory response by binding to different cell-surface proteins such as toll-like 
receptor 4, as well as oxidant-scavenging, antimicrobial and apoptosis-inducing activities are among the extra-
cellular functions attributed to CPT31. Interestingly, both pro- and anti-inflammatory roles have been reported 
for CPT32. Additionally, previous studies showed that CPT is a sensitive and specific biomarker of systemic and 
local inflammation, mirroring in the latter case intestinal or synovial inflammation (when its levels are assessed in 
stool samples or synovial fluid, respectively)33–35. Fecal CPT levels have also been associated with disease activity 
in ankylosing spondylitis (AS)24,36. Furthermore, serum CPT was shown to be an independent marker of radio-
graphic spinal progression in axSpA37. Also in this line, it was reported that CPT expression is highly upregulated 
in inflamed axial entheses in SKG mice, an experimental model of SpA38.
Taking all these considerations into account, in the present study we aimed to evaluate the potential associ-
ation of CPT with the development of subclinical atherosclerotic disease and also with metabolic risk factors, 
including lipid profile and markers of inflammation, in a large cohort of axSpA patients.
Results
Differences in CPT levels between axSpA patients and controls. axSpA patients displayed statis-
tically significantly lower CPT levels than controls (91.4 ± 26.1 vs. 102.3 ± 31.2 ng/mL, respectively, p = 0.006) 
after adjustment for sex, age at the time of the study and classic CV risk factors (Fig. 1, Table 1). No statistically 
significant differences were observed in CPT levels between AS and nr-axSpA when adjusting for sex, age at the 
time of the study, classic CV risk factors and HLA-B27 status (p > 0.05).
Association of CPT levels and markers of subclinical atherosclerosis. When we assessed the poten-
tial association of CPT levels with presence of plaques and cIMT values in axSpA, no statistically significant 
results were obtained after adjusting for sex, age at the time of the study, classic CV risk factors and HLA-B27 
status (p > 0.05).
Figure 1. Differences in CPT serum levels between healthy controls and axSpA patients, after adjustment 
for sex, age at the time of the study and traditional CV risk factors (smoking, obesity, dyslipidemia and 
hypertension). Healthy controls (n = 63) are represented by empty circles (○), while axSpA patients (n = 163) 
are represented by filled circles (●). Horizontal bars indicate mean value of each group.
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Relationship of CPT levels with routine laboratory markers of inflammation, lipid profile, dis-
ease activity and treatment. We observed a negative correlation of CPT with high density lipoprotein 
(HDL)-cholesterol (r = −0.226, p = 0.005, Fig. 2a) and a positive correlation with the atherogenic index (AI) 
(r = 0.296, p = 0.0002, Fig. 2b) in axSpA. This association between CPT and parameters of lipid profile was fur-
ther confirmed in the AS subgroup (r = −0.285, p = 0.003 for HDL-cholesterol, and r = 0.285, p = 0.003 for AI) 
and in the non-radiographic axSpA (nr-axSpA) subgroup (r = 0.371, p = 0.02 for AI). In addition, we found 
an association with C-reactive protein (CRP) levels at diagnosis in axSpA patients (r = 0.169, p = 0.03). When 
patients were stratified according to the subtype of axSpA, it was observed that this association was due to the AS 
subgroup (r = 0.188, p = 0.05). Accordingly, the mean CPT concentration in axSpA patients with CRP levels at 
diagnosis higher than 3 mg/L was more elevated than that found in patients with lower CRP levels at diagnosis 
(95.5 ± 26.4 vs. 86.8 ± 25.2 ng/mL, respectively, p = 0.01). This significant difference in CPT levels among patients 
with high/low CRP levels at diagnosis was also observed in AS (p = 0.001). No statistically significant association 
was disclosed between CPT levels and disease activity (assessed by Bath Ankylosing Spondylitis Disease Activity 
Index [BASDAI]) or markers of inflammation (CRP and erythrocyte sedimentation rate [ESR]) at the time of the 
study, or with ESR at the time of axSpA diagnosis (p > 0.05). All these results were adjusted for sex, age at the time 
of the study, classic CV risk factors and HLA-B27 status as potential confounding factors.
The different treatments that our axSpA patients were receiving at the time of the study (anti- tumour 
necrosis factor-α [anti-TNF-α] therapy, disease modifying anti-rheumatic drugs [DMARDs], nonsteroidal 
anti-inflammatory drugs [NSAIDs] and statins) were not found to exert any influence on their CPT serum levels 
after adjustment for sex, age at the time of the study, classic CV risk factors and HLA-B27 status (p > 0.05).
Variable
Controls 
(n = 63) axSpA (n = 163) AS (n = 119)
nr-axSpA 
(n = 44)
Men/Women, n 28/35 90/73 73/46 17/27
Age at study (years), mean ± SD 50.9 ± 15.3 43.7 ± 11.6 44.9 ± 11.9 40.3 ± 10.3
Age at axSpA diagnosis (years), mean ± SD — 37.2 ± 10.4 36.7 ± 10.7 38.7 ± 9.2
History of classic cardiovascular risk factors, n (%)
  Current smokers 12 (19.0) 47 (28.8) 39 (32.8) 8 (18.2)
  Obesity 12 (19.0) 32 (19.6) 25 (21.0) 7 (15.9)
  Dyslipidemia 13 (20.6) 33 (20.2) 25 (21.0) 8 (18.2)
  Hypertension 12 (19.0) 25 (15.3) 19 (16.0) 6 (13.6)
Body mass index (kg/m2) at study, mean ± SD 26.8 ± 4.9 25.9 ± 4.5 26.1 ± 4.6 25.2 ± 4.2
Systolic blood pressure (mm Hg) at study, mean ± SD 127.4 ± 15.4 128.1 ± 15.2 129.2 ± 15.0 125.2 ± 15.5
Diastolic blood pressure (mm Hg) at study, mean ± SD 78.2 ± 8.8 77.9 ± 10.0 78.0 ± 10.3 77.8 ± 9.2
Total cholesterol (mg/dL) at study, mean ± SD 202.2 ± 33.9 193.1 ± 35.6 194.9 ± 36.1 188.0 ± 34.1
HDL cholesterol (mg/dL) at study, mean ± SD 59.1 ± 16.0 55.4 ± 16.4 53.8 ± 14.8 59.5 ± 19.6
LDL cholesterol (mg/dL) at study, mean ± SD 122.0 ± 31.8 118.2 ± 30.0 120.7 ± 31.1 111.4 ± 25.8
Triglycerides (mg/dL) at study, mean ± SD 94.7 ± 47.7 97.5 ± 54.5 98.7 ± 54.4 94.3 ± 55.3
Atherogenic index (total cholesterol/HDL), mean ± SD 3.6 ± 1.1 3.7 ± 1.0 3.8 ± 1.0 3.4 ± 0.9
CRP (mg/L) at study, mean ± SD 2.9 ± 4.4 5.7 ± 9.9 6.3 ± 10.9 4.0 ± 5.8
CRP (mg/L) at axSpA diagnosis, mean ± SD — 11.5 ± 23.4 14.0 ± 26.6 4.9 ± 7.4
ESR (mm/1st hour) at study, mean ± SD 11.5 ± 4.4 11.3 ± 12.4 12.3 ± 13.3 8.4 ± 8.9
CRP at axSpA diagnosis ≥ 3 mg/L, n (%) — 86 (52.8) 71 (59.7) 15 (34.1)
ESR (mm/1st hour) at axSpA diagnosis, mean ± SD — 15.1 ± 17.9 17.2 ± 20.2 10.3 ± 10.2
BASDAI at study, median [IQ range] — 3.80 [1.75–5.50] 3.70 [1.65–4.95] 4.40 [2.60–6.10]
BASDAI at study, mean ± SD — 3.80 ± 2.22 3.60 ± 2.17 4.35 ± 2.29
Therapy at study
Anti-TNF-α treatment, n (%) — 49 (30.1) 43 (36.1) 6 (13.6)
DMARDs, n (%)* — 79 (48.5) 62 (52.1) 17 (38.6)
NSAIDs, n (%)** — 158 (96.9) 114 (95.8) 44 (100)
Statins, n (%) — 13/163 (8.0) 10/119 (8.4) 3/44 (6.8)
Carotid IMT (mm), mean ± SD — 0.608 ± 0.131 0.622 ± 0.14 0.568 ± 0.11
Carotid plaques, n (%) — 51 (31.3) 43 (36.1) 8 (18.2)
CPT (ng/mL) 102.3 ± 31.2 91.4 ± 26.1 91.4 ± 26.7 91.1 ± 24.9
Table 1. Demographical, laboratory and cardiovascular disease-related data in healthy controls and patients 
with axSpA (both AS and nr-axSpA patients). AS: Ankylosing spondylitis; axSpA: Axial spondyloarthritis; 
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CPT: Calprotectin; CRP: C-Reactive Protein; 
DMARDs: Disease Modifying Anti-Rheumatic Drugs; ESR: Erythrocyte Sedimentation Rate; HDL: High 
Density Lipoprotein; IMT: Intima-Media Thickness; IQ: Interquartile; LDL: Low Density Lipoprotein; nr-
axSpA: non-radiographic axial spondyloarthritis; NSAIDs: Nonsteroidal anti-inflammatory drugs; SD: 
Standard Deviation; TNF: Tumour necrosis factor. *Mainly sulphasalazine, median dose: 2 grams/day. **Mainly 
naproxen, median dose: 1000 milligrams/day.
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When we evaluated the association of CPT and lipid profile parameters in healthy controls, we observed a 
statistically significant correlation with HDL-cholesterol and AI after adjustment for sex, age at the time of the 
study and classic CV risk factors (r = −0.376; p = 0.004 for HLD-cholesterol, and r = 0.393; p = 0.003 for AI). No 
statistically significant association of CPT was noted regarding CRP and ESR levels at study in the controls group 
after adjustment for those potential confounding factors (p > 0.05).
Discussion
CV disease is one of the leading causes of death in axSpA patients39. In this regard, the chronic inflammatory state 
as well as the higher incidence of traditional CV risk factors and MeS features in these patients play a key role in 
the development of CV disease in axSpA15–20. The elucidation of the molecular mechanisms that are implicated 
in the onset and progression of CV disease in axSpA could help to a better understanding of this comorbidity. 
Thereby, serum biomarkers could be used as an alternative, non-invasive approach to assess CV risk in axSpA 
patients, combined with imaging techniques such as carotid ultrasound. Thereupon, during the last years, much 
effort has been made to identify circulating biomarkers of CV risk in different chronic inflammatory diseases such 
as AS. Among them, adipokines, MeS-related molecules, as well as biomarkers of endothelial cell activation and 
inflammation have been reported to exert relevant roles in the development of CV disease40. However, given the 
complex physiological effects of these molecules, the identification of the ‘perfect’ biomarker of CV risk in chronic 
inflammatory diseases for its use in the daily clinical practice has not been achieved yet. Consequently, data on 
this issue are still inconclusive and require further studies.
This prompted us to assess whether CPT, a protein released during inflammation and potentially linked to CV 
disease in inflammatory pathologies such as type 2 diabetes mellitus or Sjögren’s syndrome26–29, could be associ-
ated with subclinical atherosclerosis and metabolic risk factors in axSpA.
Current data on CPT levels in patients with axSpA are very heterogeneous. Even if most of the studies report 
higher circulating levels of this protein in these patients41–44, others do not find differences as compared to con-
trols24,36. In this study, that included a large cohort of patients with axSpA, we disclosed significantly lower CPT 
serum concentrations in our patients when compared to controls. In this regard, a recent study revealed that CPT 
levels decrease after the end of a 6-month intensive exercise programme in AS and nr-axSpA patients, accompa-
nied by clinical improvement45. This may be particularly relevant, given that regular exercise and physical therapy 
is recommended to complement medical therapy in axSpA, aimed to ameliorate physical disability as well as car-
diorespiratory complications of the disease46. Thus, it is possible that physical exercise could have an influence on 
circulating CPT levels, lowering them, and hence possibly explaining our results. Unfortunately, we could not get 
enough information on the physical activity/therapy performed by our patients. Another potential explanation 
for the decreased levels of circulating CPT observed in our patients could be that they are reflecting an accumu-
lation of CPT in the synovial fluid, based on the small size of CPT (36.5 kDa), which enables it to diffuse between 
inflamed tissues and circulation47. In this regard, previous reports have shown that CPT may diffuse from the 
inflamed joints into circulation47,48. Similarly, it has been suggested that inflammatory cells expressing CPT are 
activated and transmigrate from peripheral circulation, through the endothelium, to the inflamed tissues34,43. 
Thereby, as suggested by Levitova et al., decreased serum levels of CPT may mirror local inflammation45 (e.g. in 
synovial tissue). Even though axSpA is a predominantly axial disease, rarely presenting peripheral involvement, 
around 30% of our axSpA patients did exhibit peripheral arthritis/synovitis. Accordingly, it is possible that serum 
levels of CPT may be reflecting a certain degree of local inflammation in sacroiliac, costovertebral or facet joints, 
which are often affected in axSpA. In addition, it was reported that the levels of circulating CPT decrease after 
effective treatment in rheumatic diseases31,49. In the present study we assessed the influence of the different thera-
pies that patients were receiving at the time of the study. At this time, the different modalities of treatment did not 
show any statistically significant effect on CPT serum levels. It is important to note that, in spite of the low activity 
of the disease displayed by our patients (based on the BASDAI value), they probably still have a certain degree of 
inflammation. Thereupon, another potential hypothesis to explain our results could be that this might be trigger-
ing compensatory mechanisms to reduce the detrimental effect of this remaining inflammation (by reducing, for 
example, the levels of pro-inflammatory molecules such as CPT, either in a direct or indirect fashion).
Figure 2. Association of serum levels of CPT with HDL-cholesterol (a) and atherogenic index (b) in axSpA 
patients after adjustment for sex, age at the time of the study, classic CV risk factors and HLA-B27 status.
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Regarding the role of CPT in CV disease, as above mentioned, in previous studies this molecule has been 
linked to atherosclerosis in different chronic inflammatory diseases26–30. Among them, the only study that 
included axSpA patients was one in which 12 AS patients were studied along with 15 rheumatoid arthritis and 
9 psoriatic arthritis patients (as a single group). In such a study, it was reported that CPT associated with aortic 
stiffness, but not with cIMT values30. In our present study we did not disclose an association between CPT levels 
and cIMT values or presence of plaques, as surrogate markers of CV disease. However, when we assessed the 
potential link between CPT levels and metabolic risk factors, an association between CPT and lipid profile param-
eters emerged in our axSpA patients. In this regard, we found an inverse association between HDL-cholesterol 
and CPT in AS, and a positive correlation between this protein and the AI in both types of axSpA. These results 
on lipid association with CPT were further confirmed in our control cohort. Our results are in line with those 
obtained in previous studies, in which CPT negatively correlated with HDL-cholesterol in individuals with no 
previous history of CV disease and in obese patients27,50,51. This further supports the importance of CPT in the 
atherosclerotic process, regardless of the pathogenic context. Hence, CPT adds to a list of inflammatory markers 
that are associated with decreased HDL-cholesterol levels52. Low HDL-cholesterol levels and high AI are markers 
of inflammation and dyslipidemia, factors that further enhance the risk of developing atherosclerosis. However, 
whether this is a direct effect of CPT on lipid metabolism or an indirect effect mediated by the inflammatory 
status should be further evaluated.
In accordance with the pro-inflammatory role of CPT, in the whole group of axSpA we disclosed a positive 
association with the levels of CRP, a widely known biomarker of systemic inflammation, at the time of diagnosis 
of the disease. This was also confirmed in the subgroup of AS patients, supporting the data previously reported 
by others27,36,44. In a further analysis, we observed that axSpA patients with CRP levels at disease diagnosis higher 
than 3 mg/L, a CRP level considered representative of high vascular risk53, also showed higher serum CPT levels. 
However, in line with previous reports41,42, no association was observed between CPT and BASDAI at the time of 
the study. Similarly, no association was noted between CPT and ESR at the time of disease diagnosis, or ESR and 
CRP at the time of the study. Even if some authors have previously reported a correlation between CPT and/or 
ESR36,41, others did not find such association42. It is plausible to think that CRP and ESR levels at the time of the 
study could be under the influence of the medical treatment received, physical therapy and changes in lifestyle 
aimed to improve the quality of life of axSpA patients.
It is worth mentioning that, as occurs with other rheumatic diseases, the current tools used to predict the 
individual’s absolute risk for CV disease (such as lipid profile, CRP or other inflammatory markers) were found 
to underestimate the actual CV risk of patients with axSpA12. Consequently, the search for additional tools that 
may help to identify axSpA patients at high risk of CV events is of main importance. Thereby, we believe a com-
bination of a series of biomarkers (among them CPT), rather than the assessment of a single one, along with the 
use of non-invasive surrogate markers, such as the carotid ultrasonography, may be needed to reach an adequate 
stratification of the actual CV risk in axSpA patients.
In summary, our study shows no relationship between CPT levels and markers of subclinical atherosclerosis 
in axSpA patients undergoing therapy who had low disease activity. Nevertheless, it demonstrates that CPT is 
associated with adverse lipid profiles and inflammatory markers in a large cohort of axSpA patients. This may 
be suggesting an indirect action of this molecule on the development of atherosclerosis. The fact that lower CPT 
serum levels were observed in our patients when compared to controls warrants further investigation to deter-
mine whether axSpA-intrinsic factors, specific characteristics of our patients or even the therapy used for the 
management of the disease could be implicated in the modulation of their circulating serum CPT levels, but 
not affecting its association with CRP or parameters linked to adverse lipid profile. Moreover, further molecular 
studies are warranted to elucidate the exact mechanisms by which CPT exerts its action in the development and 
progression of atherosclerotic disease in our patients. Additionally, it will be interesting to perform comparative 
studies on the association of CPT with subclinical atherosclerosis and metabolic risk factors in other inflamma-
tory arthritides, such as psoriatic arthritis and rheumatoid arthritis.
Methods
Patients and controls. All the experiments involving humans and human blood samples were carried out in 
accordance with the approved guidelines and regulations, according to the Declaration of Helsinki. Furthermore, 
all experimental protocols were approved by the Ethics Committee of Clinical Research of Cantabria (CEIC-C, 
Number of reference 7/2016). Informed written consent was obtained from all subjects.
163 patients diagnosed with axSpA seen over a 3-year period at Hospital Universitario Marqués de Valdecilla 
and Hospital de Laredo (Cantabria, Spain) that fulfilled the ASAS classification criteria54 were recruited for this 
study. None of them had experienced CV events or had diabetes mellitus, chronic kidney disease, inflammatory 
bowel disease or psoriasis. 44 out of 163 patients fulfilled the definitions for nr-axSpA54, while the remaining 119 
patients also fulfilled definitions for AS according to the 1984 modified New York criteria55. 63 healthy controls 
(who did not have history of CV events or chronic inflammatory diseases) were also recruited for the comparative 
analysis.
Data on sex, age, body mass index (BMI), blood pressure, total cholesterol, HDL- and low density lipoprotein 
(LDL)-cholesterol, and triglycerides at the time of study, and history of traditional CV risk factors (smoking, obe-
sity, dyslipidemia and hypertension) were collected. Obesity was defined if BMI (calculated as weight in kilograms 
divided by height in squared meters) was >30. Patients were considered to have dyslipidemia if they had hyper-
cholesterolemia and/or hypertriglyceridemia (defined as diagnosis of hypercholesterolemia or hypertriglyceri-
demia by the patients’ family physician, or total cholesterol and/or triglyceride levels in fasting plasma being >220 
and >150 mg/dL, respectively). In those patients with total cholesterol between 200 and 220 mg/dL, a diagnosis 
of dyslipidemia was considered if the AI (total cholesterol/HDL-cholesterol) was ≥4.1. Patients were diagnosed 
as having hypertension if blood pressure was >140/90 mmHg or if they were taking antihypertensive agents. 
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Information on CRP and ESR at the time of the study and at disease diagnosis was assessed, as well as infor-
mation on disease activity at the time of the study (by calculating the BASDAI value) and therapy, including 
treatment with anti-TNF-α agents, DMARDs, NSAIDs and statins. The main demographic, laboratory and CV 
disease-related data of controls and patients are displayed in Table 1.
Carotid ultrasonography. Carotid ultrasonography was performed in all the patients to assess the presence 
of abnormal cIMT values in the common carotid artery and the presence of focal plaques in the extracranial 
carotid tree (as surrogate markers of CV disease), as previously reported10,11,13.
Study protocol. Determinations were made in the fasting state. Blood samples were taken for measure-
ment of ESR (Westergren), CRP (latex immunoturbidimetry) and lipids (enzymatic colorimetry). Commercial 
enzyme-linked immunosorbent assay (ELISA) kits were used to measure serum CPT (HK325, Hycult Biotech, 
the Netherlands) according to the manufacturer’s instructions. All samples were analysed in duplicate.
Statistical analysis. The analyses were first performed in the whole cohort of axSpA patients, and later 
patients were stratified into AS and nr-axSpA, since there is still concern on whether AS and nr-axSpA are dis-
tinct but overlapping disorders or two phases of the same disease56. Data were expressed as mean ± standard 
deviation (SD) and/or median [interquartile (IQ) range] for continuous variables, and number of individuals (n) 
and percentage (%) for categorical variables. Differences in CPT levels among the study groups were assessed by 
ANCOVA adjusting for potential confounding factors: sex, age at the time of the study and classic CV risk factors 
(smoking, obesity, dyslipidemia and hypertension). When comparing CPT levels between the two subtypes of 
axSpA we also performed an adjustment for ANCOVA using the above mentioned confounding factors along 
with HLA-B27 status. Correlation between CPT and continuous variables was performed via estimation of the 
Pearson partial correlation coefficient (r) adjusting for sex, age at the time of the study, classic CV risk factors and 
HLA-B27 status. Associations between categorical features and CPT concentrations were assessed by ANCOVA 
adjusting for sex, age at the time of the study, classic CV risk factors and HLA-B27 status. The correlation between 
CPT levels and continuous variables in healthy controls was performed via estimation of the Pearson partial cor-
relation coefficient (r) adjusting for sex, age at the time of the study and classic CV risk factors.
Pearson partial correlation coefficients (r) were categorized as follows: 0.1 < |r| < 0.3 = small correlation; 
0.3 < |r| < 0.5 = medium/moderate correlation; |r| > 0.5 = large/strong correlation. Two-sided p values ≤ 0.05 
were considered to indicate statistical significance. Statistical analysis was performed using STATA® v. 11.1 
(StataCorp, College Station, TX, USA).
Data Availability
All data generated or analysed during this study are included in this published article.
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